NRM-823 for Advanced or Metastatic Refractory Solid Tumors

This clinical trial focuses on testing a new drug called NRM-823, designed for people with advanced or hard-to-treat solid tumors. The trial aims to determine how safe this drug is when used alone and in combination with another type of cancer treatment known as immune checkpoint inhibitors. These inhibitors help the immune system recognize and attack cancer cells more effectively. This study is important because it explores new treatment options for patients whose tumors have not responded well to existing therapies, potentially offering new hope for managing their condition. Participants in this study will receive NRM-823 either by itself or alongside an immune checkpoint inhibitor. The study is divided into three parts. Initially, the research focuses on finding the safest dose of NRM-823 alone. After identifying this dose, the research will test its effects further in a larger group. In the final part, the study will examine how well the drug works when combined with the checkpoint inhibitor. The main focus is to observe any side effects participants might experience and to evaluate how the combination impacts the tumors. The results will help determine the best way to use these treatments together in the future.